Veradermics MANE
NYSE MANE
$116.74 -0.51 (-0.43%)
At close: Oct 2, 2026 · 4:00 PM EDT

Veradermics (MANE) Return on Capital Employed [ROCE] (2026)

Updated

Veradermics (MANE) posted Return on Capital Employed [ROCE] of -14.74% for Q2 2026.

Analysis

Veradermics (MANE) Return on Capital Employed [ROCE] (2026) Analysis & Trends

For FY2025, Veradermics' Return on Capital Employed [ROCE] came in at -76.21%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 46.74%
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 17.83%
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 17.92%
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn 6.28%
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 19.32%
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 9.54%
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 16.66%
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -5.97%
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn 11.86%
10 Veradermics 4.90 Bn 4.90 Bn - -14.74%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -14.74%
API Access

Veradermics Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=MANE&period=max&api_key=YOUR_API_KEY